Critique of the high-dose chemotherapy studies in breast cancer: A positive look at the data

Journal of Clinical Oncology

Volumn 17, Issue 11 SUPPL., 1999, Pages 30-34

  Antman, Karen H ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RESEARCH; CONFERENCE PAPER; DRUG MEGADOSE; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SCANDINAVIA; SOUTH AFRICA; SURVIVAL RATE; UNITED STATES;

EID: 0032758104     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Peters WP, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 2)
2. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
3. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from national surgical adjuvant breast and bowel project B-25. (in press)
4. Rodenhuis S, Richel KJ, Wall EVD, et al: Randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 352:515-521, 1998
5. Hortobagyi GN, Buzdar AU, Champlin R, et al: Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer: A randomized trial. Proc Am Soc Clin Oncol 17:123, 1998 (abstr 471)
6. Lotz JP, Cure H, Janvier M, et al: High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: Results of the French protocol Pegase 04. Proc Am Soc Clin Oncol 18:43a, 1999 (abstr 161)
7. Peters W, Jones R, Vredenburgh J, et al: A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 15:121, 1996 (abstr)
8. Bezwoda W, Seymour L, Dansey R: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
9. Bezwoda WR: Randomised, controlled trial of high dose chemotherapy versus standard dose chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 18:2a (abstr4) 1999
10. Bergh J: Results from a randomized adjuvant breast cancer study with high-dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose-escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 3)
11. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
12. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
13. Philip T, Guglielmi C, Hagenbeek A, et al: The Parma international randomized prospective study in relapsed nonHodgkin's Lymphoma; second interim analysis of 172 patients. Proc Eur Group Bone Marrow Transplant 18:203, 1992 (abstr 402)
14. Stadtmauer EA, O'Neill A, Goldstein LJ, et al: Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia intergroup study. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 1)
15. Rowlings PA, Williams SF, Antman KH, et al: Factors correlated with progression-free survival after high-dose therapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (in press)